Altogether, SGLT2 inhibitors did not alter the risk of fatal and nonfatal stroke in high-risk type 2 diabetic patients (HR, 0.92; 95% CI, 0.77–1.10; p = 0.36), but there was a substantial heterogeneity (I2 = 63%; p = 0.064) (Fig. 3B). The gene discussed is SLC5A2; the disease is Stroke.